Patent Application
20080020060
A colloidal suspension comprising nanoparticles of elemental silver is provided. The colloidal suspension comprises de-ionized water and 99.99% pure silver. The colloidal suspension comprises approximately 20 ppm silver.
The foregoing colloidal suspension comprising substantially pure silver is mixed with an over-the-counter rhinitis remedy. Examples of over-the-counter rhinitis medicines which may be used in the practice of the invention include AFRIN® (oxymetazoline HCl), NEO-SYNEPHRINE® (phenylephrine HCl 1.0%); and DRISTAN® (oxymetazoline HCl 0.05%).
The colloidal suspension of substantially pure elemental silver and the selected over-the-counter rhinitis medicine are mixed at a ratio of 1:1. The resulting mixture is thereafter administered into the nostrils of a rhinitis patient in the form of a spray. It has been found that a once daily administration of the foregoing mixture is sufficient to substantially completely control rhinitis.
A colloidal suspension comprising nanoparticles of elemental silver is provided. The colloidal suspension comprises de-ionized water and 99.99% pure silver. The colloidal suspension comprises approximately 20 ppm silver.
The foregoing colloidal suspension comprising substantially pure silver is mixed with a prescription rhinitis remedy. Examples of prescription rhinitis medicines which may be used in the practice of the invention include FLONASE® (fluticasone propionate) NASONEX® (mometasone furoate monohydrate), NASACORT® (triamcinolone acetonide, and BECONTAS AQ® (beclomethasone dipropionate, monohydrate).
The colloidal suspension of substantially pure elemental silver and the selected prescription rhinitis medicine are mixed at ratio of 1:1. The resulting mixture is thereafter administered into the nostrils of a rhinitis patient in the form of a spray. It has been found that a once daily administration of the foregoing mixture is sufficient to substantially completely control rhinitis.
A colloidal suspension comprising nanoparticles of one or more alloys of silver is provided. The colloidal suspension comprises de-ionized water and one or more substantially pure silver alloys. The colloidal suspension may comprise approximately 20 ppm of one or more silver alloys. The elements that may be alloyed with silver for use in the practice of the invention include the following: Sn, Zn, Au, Pt, Pd, Co, Rh, Ir, Mn, Ti, and Zr.
The foregoing colloidal suspension comprising substantially one or more alloys of silver is mixed with an over-the-counter rhinitis remedy. Examples of over-the-counter rhinitis medicines which may be used in the practice of the invention include AFRIN® (oxymetazoline HCl), NEO-SYNEPHRINE® (phenylephrine HCl 1.0%), and DRISTAN® (oxymetazoline HCl 0.05).
The colloidal suspension of one or more alloys of silver and the selected over-the-counter rhinitis medicine are mixed at a ratio of 1:1. The resulting mixture is thereafter administered into the nostrils of a rhinitis patient in the form of a spray. It has been found that a once daily administration of the foregoing mixture is sufficient to substantially completely control rhinitis.
A colloidal suspension comprising nanoparticles of one or more alloys of silver is provided. The colloidal suspension comprises de-ionized water and one or more substantially pure silver alloys. The colloidal suspension may comprise approximately 20 ppm of one or more silver alloys. The elements that may be alloyed with silver for use in the practice of the invention include the following: Sn, Zn, Au, Pt, Pd, Co, Rh, Ir, Mn, Ti, and Zr.
The foregoing colloidal suspension comprising substantially pure silver is mixed with a prescription rhinitis remedy. Examples of prescription rhinitis medicines which may be used in the practice of the invention include FLONASE® (fluticasone propionate); NASONEX® (mometasone furoate monohydrate), NASACORT® (triamcinolone acetonide), and BECONAS AQ® (beclomethasone dipropionate, monohydrate).
The colloidal suspension of substantially pure elemental silver and the selected prescription rhinitis medicine are mixed at a ratio of 1:1. The resulting mixture is thereafter administered into the nostrils of a rhinitis patient in the form of a spray. It has been found that a once daily administration of the foregoing mixture is sufficient to substantially completely control rhinitis.
Although preferred embodiments of the invention have been illustrated in the accompanying Drawings and described in the foregoing Detailed Description, it will be understood that the invention is not limited to the embodiments disclosed, but is capable of numerous rearrangements, modifications, and substitutions of parts and elements without departing from the spirit of the invention.
Applicant claims priority based on provisional patent application Ser. No. 60/820,003 filed Jul. 21, 2006, the entire content of which is incorporated herein by reference.
| Number | Date | Country | |
|---|---|---|---|
| 60820003 | Jul 2006 | US |
